Accepted for/Published in: JMIR Research Protocols
Date Submitted: Aug 24, 2022
Date Accepted: Dec 8, 2022
The protocol of EPI-589 early Phase 2 Investigator-initiated Clinical trial for ALS (EPIC-ALS): A multi-center, open-labeled, 24-week, single-group, exploratory trial of EPI-589 in amyotrophic lateral sclerosis
ABSTRACT
Background:
Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disorder, with its currently approved drugs, including riluzole and edaravone, showing limited therapeutic effects. Therefore, safe and effective drugs are urgently necessary. EPI-589 is an orally available, small molecule, novel redox-active agent characterized by highly potent protective effects against oxidative stress with high blood–brain barrier permeability. Given the apparent oxidative stress and mitochondrial dysfunction involvement in the pathogenesis of ALS, EPI-589 may hold promise as therapeutic.
Objective:
Here we describe the design and rationale for the EPI-589 early Phase 2 Investigator-initiated Clinical trial for ALS (EPIC-ALS).
Methods:
EPIC-ALS is an explorative, open-labeled, single-arm trial that evaluates the efficacy, safety, and biomarkers of EPI-589 in patients with ALS. This trial consists of 12-week run-in, 24-week treatment and 4-week follow-up periods. Patients will receive 500 mg of EPI-589 three times daily over the 24-week treatment period. Efficacy assessments include the mean monthly change of Amyotrophic Lateral Sclerosis Functional Rating Scale–Revised total score. The biomarkers were selected to analyze the effect on oxidative stress and neuronal damage. The plasma biomarkers include 8-hydroxy-2’-deoxyguanosine, 3-nitrotyrosine, neurofilament light chain (NfL), phosphorylated neurofilament heavy chain (pNfH), homocysteine, and creatinine. The cerebrospinal fluid biomarkers include 8-hydroxy-2’-deoxyguanosine, 3-nitrotyrosine, NfL, pNfH, and ornithine. The magnetic resonance biomarkers include fractional anisotropy in the corticospinal tract and N-acetylaspartate in the primary motor area.
Results:
This trial began data collection in September 2021 and is expected to be completed in October 2023.
Conclusions:
This study can provide data regarding the safety, efficacy, and biomarkers of EPI-589. These data will be useful to understand the characteristics of EPI-589. Clinical Trial: JRCT ID: jRCT2061210031; https://rctportal.niph.go.jp/en/detail?trial_id=jRCT2061210031
Citation
Request queued. Please wait while the file is being generated. It may take some time.
Copyright
© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.